首页 | 本学科首页   官方微博 | 高级检索  
检索        


Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis
Institution:1. Service de pharmacotoxicologie, hospices civils de Lyon, CHU de Lyon, 69424 Lyon, France;2. CNRS, laboratoire de biométrie et biologie évolutive UMR5558, université Lyon, université Lyon 1, 69622 Villeurbanne, France;3. Service de pharmacologie clinique, CHRU de Tours, 37044 Tours, France;4. UMR 7292 GICC, CNRS, 37044 Tours, France;5. Université François-Rabelais, 37044 Tours, France;6. University College of General Medicine, University Claude-Bernard Lyon 1, 69000 Lyon, France;7. Département de médecine générale, université de Poitiers, 86073 Poitiers, France;8. Fédération d’endocrinologie, maladies métaboliques, diabète et nutrition, hospices civils de Lyon, hôpital Louis-Pradel, 69500 Bron, France;9. Inserm U1060, université Lyon 1, 69622 Villeurbanne, France
Abstract:AimRecent US recommendations indicate a target blood pressure (BP) of 130/80 mmHg for patients with type 2 diabetes (T2D). Our aim was to characterize the association between risk of cardiovascular events and differences in BP decreases in randomized trials of a T2D population.MethodsA systematic search was made for randomized clinical trials assessing the effects of antihypertensive treatments in T2D patients on mortality, and fatal and non-fatal cardiovascular events, using a meta-regression technique to explore the influence of BP decreases on treatment effects.ResultsA total of 88,503 patients from 44 randomized trials were included. There was no significant association between BP decreases and risk of all-cause or cardiovascular mortality, cardiovascular events or myocardial infarction. However, stroke risk was influenced by BP decreases: compared with no reduction, a 10-mmHg reduction in systolic BP was associated with a relative odds ratio (OR) decrease of 33% (OR: 0.67, 95% CI: 0.54–0.82), and a 5-mmHg diastolic BP reduction was associated with a relative OR decrease of 38% (OR: 0.62, 95% CI: 0.50–0.76). Restricting the analysis to double-blind studies did not change the results for diastolic BP.ConclusionA reduction in BP lowers the risk of stroke, but does not appear to affect the risk of other cardiovascular events in a T2D population.
Keywords:Antihypertensive treatment  Cardiovascular diseases  Diabetes mellitus  Meta-regression  Type 2  ACC"}  {"#name":"keyword"  "$":{"id":"kw0035"}  "$$":[{"#name":"text"  "_":"American College of Cardiology  ACE"}  {"#name":"keyword"  "$":{"id":"kw0045"}  "$$":[{"#name":"text"  "_":"Angiotensin-converting enzyme  AHA"}  {"#name":"keyword"  "$":{"id":"kw0055"}  "$$":[{"#name":"text"  "_":"American Heart Association  BP"}  {"#name":"keyword"  "$":{"id":"kw0065"}  "$$":[{"#name":"text"  "_":"Blood Pressure  CV"}  {"#name":"keyword"  "$":{"id":"kw0075"}  "$$":[{"#name":"text"  "_":"Cardiovascular  CVD"}  {"#name":"keyword"  "$":{"id":"kw0085"}  "$$":[{"#name":"text"  "_":"Cardiovascular Disease  DBP"}  {"#name":"keyword"  "$":{"id":"kw0095"}  "$$":[{"#name":"text"  "_":"Diastolic Blood Pressure  FDA"}  {"#name":"keyword"  "$":{"id":"kw0105"}  "$$":[{"#name":"text"  "_":"Food and Drug Administration  OR"}  {"#name":"keyword"  "$":{"id":"kw0115"}  "$$":[{"#name":"text"  "_":"Odds Ratio  RCT(s)"}  {"#name":"keyword"  "$":{"id":"kw0125"}  "$$":[{"#name":"text"  "_":"Randomized Clinical Trial(s)  REML"}  {"#name":"keyword"  "$":{"id":"kw0135"}  "$$":[{"#name":"text"  "_":"Restricted Maximum Likelihood  SBP"}  {"#name":"keyword"  "$":{"id":"kw0145"}  "$$":[{"#name":"text"  "_":"Systolic Blood Pressure  T2D"}  {"#name":"keyword"  "$":{"id":"kw0155"}  "$$":[{"#name":"text"  "_":"Type 2 Diabetes
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号